- Generic drugmakers gain key victory in ‘skinny label’ patent case<figure><div><img src="https://imgproxy.divecdn.com/ziTZorQlSmji768zIR1l1ktFtiVk9NxBSdR62q8K0IA/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjA4NzE3Njg0LmpwZ…BioPharma Dive · 1mo ago↗ source
- Innovent declares Phase 3 success for ADC that attracted huge Takeda dealInnovent Biologics' ADC candidate has passed a Phase 3 trial in advanced stomach cancer and is under priority review in China, but details of the success are still under wraps. The Phase 3 win wi…Endpoints · 1mo ago↗ source
- Fulcrum lays off majority of staff; Seres extends runway into 2027👥 Fulcrum Therapeutics reduced to a shell: The biotech is letting go 48 of its 57 full-time employees, according to an SEC filing. The step comes after Fulcrum said